What is claimed is:

10

15

20

 A method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of soluble receptor for advanced glycation endproducts (sRAGE).

- The method of claim 1, wherein the subject is human.
 - wherein the of claim 1, 3. The method therapeutically effective amount of sRAGE is an about 150 sRAGE/kg μg amount between subject/day and 15 mg sRAGE/kg of subject/day, or its equivalent.
 - wherein the method of claim 1. 4. The therapeutically effective amount of sRAGE is an about 500 μg sRAGE/kg amount between subject/day and 5 mg sRAGE/kg of subject/day, or its equivalent.
- claim · 1, wherein the of The method 5. sRAGE is therapeutically effective amount of 25 subject/day, its or 1.5 mg/kg of about equivalent.
- 6. A method for inhibiting CD4⁺ T-cell migration comprising contacting the CD4⁺ T-cell with soluble receptor for advanced glycation endproducts (sRAGE).

7. The method of claim 6, wherein the CD4⁺ T-cell is a human cell.

- 5 8. The method of claim 6, wherein the CD4⁺ T-cell is present in a subject, and the contacting with sRAGE is performed by administering a therapeutic amount of sRAGE to the subject.
- 10 9. The method of claim 8, wherein the subject is human.
- 8, wherein claim ο£ The method 10. therapeutically effective amount of sRAGE is an of 150 μg sRAGE/kg between about amount 15 subject/day and 15 mg sRAGE/kg of subject/day, or its equivalent.
- the 8, wherein o£ claim The method 11. therapeutically effective amount of sRAGE is an 20 sRAGE/kg of about between 500 μg amount subject/day and 5 mg sRAGE/kg of subject/day, or its equivalent.
- the 8, wherein claim The method ο£ 12. 25 amount of sRAGE is therapeutically effective of subject/day, its or 1.5 mg/kg about equivalent.
- 30 13. A method for inhibiting chemokine receptor activation in a subject comprising administering to the subject a therapeutically effective amount

of soluble receptor for advanced glycation endproducts (sRAGE).

14. The method of claim 13, wherein the subject is human.

5

10

25

30

- 15. The method of claim 13, wherein the chemokine receptor is selected from the group consisting of CCR1, CCR2, CCR5, CXCR2, CXCR4, VCAM-1, VLA-4, MMPS receptor, RANTES receptor, MIP-1β receptor, MIP-1a receptor, MIP-2 receptor, JE/MCP-1 receptor and TCA-3 receptor.
- claim 13, wherein the The method of 16. therapeutically effective amount of sRAGE is an 15 150 sRAGE/kg between about μg subject/day and 15 mg sRAGE/kg of subject/day, or its equivalent.
- claim 13. wherein the 17. The method of 20 therapeutically effective amount of sRAGE is an between about 500 μq sRAGE/kg of amount mg sRAGE/kg of subject/day, subject/day and its equivalent.
 - 13, wherein the claim 18. The method of is amount of sRAGE therapeutically effective its mg/kg of subject/day, about 1.5 or equivalent.
 - 19. An article of manufacture comprising (a) a packaging material having therein soluble

receptor for advanced glycation endproducts (sRAGE) and (b) instructions for using the sRAGE in treating multiple sclerosis.

20. An article of manufacture comprising (a) a packaging material having therein soluble receptor for advanced glycation endproducts (sRAGE) and (b) instructions for using the sRAGE in inhibiting CD4⁺ T-cell migration in a subject.

10

21. An article of manufacture comprising (a) a packaging material having therein soluble receptor for advanced glycation endproducts (sRAGE) and (b) instructions for using the sRAGE to inhibit cytokine receptor activation in a subject.

20

15

25

30